1. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815–32
2. Boxenbaum H (1999) Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of K i and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 2:47–52
3. DeGrendele H (2003) Activity of the Raf kinase inhibitor BAY 43–9006 in patients with advanced solid tumors. Clin Colorectal Cancer 3:16–18
4. Food and Drug Administration (FDA) (1999) Guidance for Industry entitled, “In vivo Drug metabolism/Drug interaction studies—study design, data analysis, and recommendations for dosing and labeling, US Department of Health and Human Services, Food and Drug Administration, Rockville, MD. Website: http://www.fda.gov/cber/gdlns/metabol.pdf
5. Gibbs MA, Thummel KE, Shen DD, Kunze KL (1999) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180–187